Form Of Active Pharmaceutical Ingredient Research Articles

Stability screening of pharmaceutical cocrystals

An efficient protocol for assessing both the chemical and physical stability of cocrystalline forms of active pharmaceutical ingredients (APIs) is proposed. In this protocol, the cocrystalline material is used to prepare two standard formulations, mimicking wet granulations, to make low-dose tablets. After designed stress testing at a range of temperatures and RH conditions, degradant formation is modeled from the data using ASAPprime ® to determine if the tablets have a minimum of a one-year shelf-life (25 °C/60% RH open). When the cocrystals provide a kinetic solubility enhancement over the un-complexed API, a physical assessment of the cocrystal stability is carried out using the same tablets at selected stress conditions. For this assessment, kinetic solubility (where the amount of buffer used to dissolve the tablet is adjusted to completely dissolve the cocrystalline form but leave most of the un-complexed form out of solution) changes are used to indicate whether there is a significant risk for physical instability on long-term storage. This process was exemplified using model cocrystals of APIs.

Deep Eutectic Solvents and Pharmaceuticals

Deep eutectic solvents (DES) are eutectic mixtures that present a deviation from the ideal thermodynamic solid–liquid phase behavior, where a significant depression in the melting temperature occurs. If properly designed and chosen, DES may be liquid at room and the human body’s temperatures and display a biocompatible character, thus representing relevant options in the pharmaceutical field. Accordingly, DES have been studied as alternative solvents or in formulations of pharmaceuticals to improve their solubility and stability. Depending on the DES components, these mixtures might exhibit interesting biological activities compatible with several applications. The use of DES as functional agents or as novel liquid forms of active pharmaceutical ingredients (API-DES) with the goal of improving bioavailability, permeability and therapeutic efficacy of a given API stands as alternative strategies in the pharmaceutical field for drug delivery purposes.

Formation of low melting point binary systems comprising ketoprofen and an amide local anaesthetic

Liquid forms of active pharmaceutical ingredients, ionic liquids (ILs) and deep eutectic mixtures (DEMs), offer several potential benefits in respect to advancing pharmaceutical formulations. The aim of this study was to develop and characterise ILs/DEMs composed of two active molecules: ketoprofen (KET), as the acidic component, and a local anaesthetics (LA), lidocaine (LID), mepivacaine (MEP) or bupivacaine (BUP), which constituted the basic component. A mechanosynthetic approach was successfully applied to obtain LA-KET low melting systems. Composition/temperature phase diagrams were determined by differential scanning calorimetry. The amide LA-KET mixtures showed a eutectic behaviour during heating and formed viscous liquids upon quench cooling. Considering the quench cooled LA-KET mixtures, LA crystallisation was observed only in the LA-rich mixtures. LID, MEP and BUP formed disordered complexes with KET at an approximate 1:2 stoichiometry. Infrared spectroscopy studies revealed that the mixtures were composed mainly of hydrogen bonded acid and base molecules, but small amounts of carboxylate anions were detected. The formation of LA-KET complex not only suppressed the high crystallisation tendency of the LA molecules in the dry state, but also eliminated the crystallisation of KET and LA molecules induced by moisture, as revealed by dynamic vapour sorption studies.

Vírusellenes terápiás lehetőségek COVID–19 fertőzés kezelésére

Összefoglaló. A COVID–19-járvány egyre növekvő számú fertőzött betegének ellátása érdekében rövid időn belül szükség mutatkozott vírusellenes terápiás lehetőségekre. A gyors reagálás szempontját figyelembe véve erre a célra elsősorban más vírusok ellen már kifejlesztett vírusellenes szerek jöhetnek szóba. A magyar betegek ellátásbiztonsága szempontjából különösen fontos a hatóanyagok és gyógyszerkészítmények hazai gyártása. Ezt a cél tűzte ki a favipiravir, egy széles spektrumú antivirális hatóanyag hazai fejlesztése, amely sikeresen befejeződött, a gyógyszerkészítmény klinikai vizsgálata folyamatban van. Summary. Increasing impact of COVID-19 on the healthcare system prompted the identification of potential antiviral therapies. Due to the immediate demand, known drugs were subjected to repositioning attempts. These drugs include agents inhibiting the viral entry into the host cells, drugs potentially blocking the release of the viral RNA from the endosomes, antivirals inhibiting the replication of the viral RNA and finally compounds that might prevent the assembly of the new virion. Since there is less experience with camostat and nafamostat, the entry inhibitors tested in Japan, and due to the ambiguous data collected with the endosome blocking chloroquine and hydroxyl-chloroquine, we focused on the actual antiviral treatment options for COVID-19 infections. In addition to favipiravir and remdesivir that were used early, at the onset of the pandemic, we discuss novel candidates including molnupiravir, a promising antiviral actually investigated in clinical trials. Considering the needs of Hungarian COVID patients and the security of supply as first priority, we selected favipiravir and developed a convenient process for the industry-scale production of the active pharmaceutical ingredient (API). At the end of this review we summarize the development and clinical investigation of favipiravir, a wide spectrum antiviral drug used for the treatment of mild and moderate COVID patients in Hungary in both ambulant and clinical settings. The Hungarian COVID Task Force set up two consortia, one for the development and the other for the clinical investigations of favipiravir. The objective of the favipiravir development consortium was to develop processes for the production of Favipiravir API and dosage forms. The consortium completed the pilot plant scale industrial production of the API and produced clinical samples for the upcoming trials. The selection and laboratory scale optimization of the synthesis route was performed at the Medicinal Chemistry Research Group of the Research Center for Natural Sciences. The laboratory scale synthesis was scaled up for pilot plant production at EVI plc and Gedeon Richter plc. GMP production was realized at the facilities of Gedeon Richter plc. Finished dosage forms were developed at Meditop Ltd who produced the clinical samples under GMP conditions. The clinical consortium is headed by the Hungarian section of the European Clinical Research Infrastructure Network (ECRIN) and organized two trials. One of these trials investigates favipiravir produced in Hungary while the other trial is performed with favipiravir produced in Japan. Both studies were approved by the Hungarian regulatory agency (OGYÉI) and are ongoing.

Mathematically assisted UV-spectrophotometry as a greener alternative to HPLC-UV for quality control analysis of free-drug combinations

Here we introduce a novel and a comprehensive evaluation of the eco-friendliness of UV-spectrophotometry versus HPLC-UV, as used for the quality control testing of free-drug combinations. We offer a new perspective to improve the sustainability of quality control testing of pharmaceuticals, through utilization of UV-spectrophotometry coupled to mathematical signal processing as means to improve selectivity of analysis of multicomponent pharmaceutical samples. First, we developed two novel analytical methods based on UV-spectrophotometry and HPLC-UV, for the simultaneous determination of antidiabetic free-drug combination consisting of dapagliflozin (DAPA) and saxagliptin (SAXA), in the form of active pharmaceutical ingredients or finished pharmaceutical products. Furthermore, we perform qualitative and quantitative evaluation of methods’ greenness employing five reported tools namely: National Environmental Methods Index (NEMI), Raynie and Driver’s assessment tool, Green Analytical Procedure Index (GAPI), Eco-scale and Analytical GREEnness Metric (AGREE). Our results indicate that both methods were equally efficient in quantifying target analytes in the studied forms, however, UV-spectrophotometry was found to be superior to HPLC-UV from a green analytical chemistry perspective, with more than 20 folds reduction in organic solvent consumption, ~ 10 folds reduction in energy consumption and ~4 folds reduction in analysis time, making it a safer alternative to consider.

A Compact Analytical Profile of Aripiprazole: Analytical Methodologies

Aripiprazole (APZ) is an antipsychotic drug that belongs to benzisoxazole derivatives and is used to treat schizophrenia as well as acute manic or mixed effects in patients with bipolar 1 disorder. APZ is used to treat certain mental, mood disorders such as bipolar disorder, Schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder. It may also be used in combination with other medication to treat depression. The present review article would be useful for prospective studies for researchers interested in APZ formulation production and quality management. Using a thorough computer assisted literature survey; this review touches upon the various reported analytical methods for the quantification of APZ both in API (Active Pharmaceutical Ingredient) and pharmaceutical dosage forms. The present write-up also encompasses the various published research articles like Spectroscopy techniques, X- Ray Diffraction (XRD), Electro Chemical Technique, Differential Scanning Calorimeter (DSC) and Capillary Electrophoresis. This is the first review article in this series with focus on the analytical profile of APZ. Although, several methods were reported in the literature, HPLC stands out first for the quantification of APZ.

Quantitation of Commercially Available API Solid Forms by Application of the NMR-qSRC Approach: An Optimization Strategy Based on In Silico Simulations.

Physical forms of active pharmaceutical ingredients (APIs) play a crucial role in drug discovery since 85% of API molecules exhibit polymorphism and sometimes complicated phase behavior, often resulting in important differences in the respective biochemical and physical properties. Characterization and quantitation of the different forms are becoming more and more essential in the pharmaceutical industry: once these characteristics are known, it is easier to choose the best solid form for development, formulation, manufacturing, and storage. Time domain-nuclear magnetic resonance (TD-NMR) has recently been used to develop a quantitation protocol for solid mixtures, named qSRC, based on the linear combination of T1 saturation recovery curves (SRCs) collected on a bench-top instrument. Despite its potentials and ease of use, a limited number of application cases have been reported in the literature since its development and many aspects remain to be clarified for the technique to be adopted as a robust routinely industrial analytical tool. In the present work, the reliability of the qSRC approach has been studied by focusing on the role played by key experimental variables, including mixture composition, signal-to-noise ratio, and T1 differences. In silico simulations were carried out for a wide range of theoretical cases to predict the expected level of accuracy obtainable for a given sample-parameter acquisition set and to clearly define the range of applicability of the method. Results of the simulation are presented alongside a comparison with three real-case studies of commercially available APIs: piroxicam, naproxen sodium, and benzocaine.

Solid state characterization, solubility, intrinsic dissolution and stability behavior of allopurinol hydrochloride salt

Since each solid form of an active pharmaceutical ingredient (API) can exhibit particular physicochemical properties, the objectives of this work were to characterize and study the solubility/stability properties of allopurinol hydrochloride salt (ALO-HCl) for the first time. ALO-HCl was obtained through an unreported recrystallization process and studied by X-ray powder diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). All characterization techniques were effective for the differentiation of ALO-HCl from the preferred pharmaceutical form (ALO). DSC and TGA studies showed a solid-state conversion from ALO-HCl to ALO upon HCl loss. Solubility and dissolution tests showed that ALO-HCl converts to ALO in aqueous media. Moreover, the effect of the common ion decreased the amount of drug released from ALO-HCl during the intrinsic dissolution assay in HCl medium. The stability studies showed a partial conversion from ALO-HCl to ALO after 6 months of storage. The results indicate that comparative studies between crystalline forms of APIs are of great importance, as they contribute to the understanding of aspects related to the quality of medicines.

Ionic Liquids in Drug Delivery

Ionic liquids (ILs) are molten salts composed of a large organic cation and an organic/inorganic anion. Due to their ionic character, most ILs present advantageous properties over conventional solvents, such as negligible volatility at atmospheric conditions and high thermal and chemical stabilities. The wide variety of IL anion–cation combinations allows these solvents to be designed to display a strong solvation ability for a myriad of active pharmaceutical ingredients (APIs) and (bio)polymers. Given these properties, ILs have been used as solvents and as formulation components in different areas of drug delivery, as well as novel liquid forms of APIs (API-ILs) applied in different stages of development of novel drug delivery systems. Furthermore, their combination with polymers and biopolymers has enabled the design of drug delivery systems for new therapeutic routes of administration.

Stabilization of Metastable Indomethacin α in Cellulose Nanocrystal Aerogel Scaffolds.

Indomethacin (IM) is a small molecule active pharmaceutical ingredient (API) that exhibits polymorphism with the γ-form being the most thermodynamically stable form of the drug. The α-form is metastable, but it exhibits higher solubility, making it a more attractive form for drug delivery. As with other metastable polymorphs, α-IM undergoes interconversion to the stable form when subjected to certain stimuli, such as solvent, heat, pH, or exposure to seed crystals of the stable form. In this study, IM was crystallized into cellulose nanocrystal aerogel scaffolds as a mixture of the two polymorphic forms, α-IM and γ-IM. Differential scanning calorimetry (DSC) and Raman spectroscopy were used to quantitatively determine the amount of each form. Our investigation found that the metastable α-IM could be stabilized within the aerogel without phase transformation, even in the presence of external stimuli, including heat and γ-IM seed crystals. Because interconversion is often a concern during production of metastable forms of APIs, this approach has important implications in being able to produce and stabilize metastable drug forms. While IM was used as a model drug in this study, this approach could be expanded to additional drugs and provide access to other metastable API forms.

Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization.

Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation.

Pharmaceutical Hydrates Analysis—Overview of Methods and Recent Advances

This review discusses a set of instrumental and computational methods that are used to characterize hydrated forms of APIs (active pharmaceutical ingredients). The focus has been put on highlighting advantages as well as on presenting some limitations of the selected analytical approaches. This has been performed in order to facilitate the choice of an appropriate method depending on the type of the structural feature that is to be analyzed, that is, degree of hydration, crystal structure and dynamics, and (de)hydration kinetics. The presented techniques include X-ray diffraction (single crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD)), spectroscopic (solid state nuclear magnetic resonance spectroscopy (ssNMR), Fourier-transformed infrared spectroscopy (FT-IR), Raman spectroscopy), thermal (differential scanning calorimetry (DSC), thermogravimetric analysis (TGA)), gravimetric (dynamic vapour sorption (DVS)), and computational (molecular mechanics (MM), Quantum Mechanics (QM), molecular dynamics (MD)) methods. Further, the successful applications of the presented methods in the studies of hydrated APIs as well as studies on the excipients’ influence on these processes have been described in many examples.

X-ray Powder Diffraction Spectroscopy as a Robust Tool in Early Predicting Bioavailability of Pharmaceutical Formulation Containing Polymorphic Drug Substance

: X-ray powder diffraction (XRPD) is a unique, solid-state analytical tool used to study the 3D structure of small or macromolecules by their x-ray diffraction or scattering patterns. X-ray diffraction by a crystal reflects the periodicity of crystal architecture; any imperfections within the crystal architecture can be easily identified by its poor diffraction pattern. Recently, an open crystallography database reported that more than 85 % of drug compounds are crystalline and exist in different polymorphic states. Physicochemical properties of pharmaceutical drug products composed of active pharmaceutical ingredients (APIs) and excipients are interdependent on the physical state and forms in which APIs are distributed in excipients that determine the in-vivo and ex-vivo performance of the product. Amorphous APIs have relatively higher dissolution and bioavailability than crystalline form but with lower phase stability. During the formulation development and storage phase, the conversion is higher that largely impacts the bioavailability of the drug product. In this manuscript, we have presented the case study of itraconazole and apigenin; both are crystalline APIs, that, with the help of solid dispersion technology, are converted into amorphous drug products with enhanced oral bioavailability. The realtime monitoring of the physical form of API in the formulation was possible with the help of XRPD and other supporting data obtained from differential scanning calorimeter (DSC), which can be correlated with the dissolution and in-vivo performance of the formulation.

Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.

Active pharmaceutical ingredient (API)-based ionic liquids (API-ILs) present an exciting new paradigm for the formulation of poorly water-soluble drugs. In this study, a model room temperature API-IL (1-butyl-3-methyl imidazolium ibuprofenate) was demonstrated to be not just highly soluble but fully miscible and hence have effectively unlimited solubility in water, compared to 0.021 mg mL-1 solubility for the ibuprofen API. Solutions of the API-IL were found to be stable for up to 2 years, indicating that they have the potential to offer thermodynamic stability upon release, avoiding in vivo recrystallization issues that can limit the bioavailability of amorphous solid dispersions (ASDs) and some high-energy crystalline forms. The ibuprofen API-IL was successfully spray-dried into a polymer carrier in loadings of up to 75% w/w in order to transform it into a solid powder suitable for oral solid dosage (OSD) formulation. From modulated differential scanning calorimetry, hot-stage microscopy, powder X-ray diffraction, and attenuated total reflectance Fourier transform infrared spectroscopy measurements, the mechanism by which this high loading was achieved is based on the immiscibility between the polymer and API-IL, with the polymer encapsulating the phase-separated API-IL. Dissolution studies showed that solidification of the API-IL into microcapsules by spray drying in this manner had no detrimental effect on release characteristics. Failure to dissolve crystalline API forms into the polymer matrix eliminates the solubility enhancement of ASDs but not for highly soluble or fully miscible API-ILs. Furthermore, miscible API-IL/polymer dispersions at high loadings were found to possess less-favorable physical properties because of melting point depression, resulting, in some cases, in a failure to form a viable powder. As such, microencapsulated API-ILs at high loadings in immiscible or low-miscibility polymers that have solubility enhancement of the API-IL form, while providing solid powders for processing, represent a promising new platform for the formulation of poorly soluble compounds as OSDs.

HILIC-MS determination of dimethylamine in the active pharmaceutical ingredients and in the dosage forms of metformin

A sensitive and specific hydrophilic interaction chromatography (HILIC) method for the separation and determination of dimethylamine (DMA) in active pharmaceutical ingredients (APIs) and in dosage forms of metformin (MET) has been developed and validated. A feasible analytical method based on HILIC coupled with mass spectrometry detection (HILIC-MS) was established using a simple sample preparation. The separation of MET was achieved on a Cortecs HILIC column using a mixture of 10 mmol/L ammonium formate adjusted to pH 4.8 and acetonitrile (25:75, v/v) at 0.8 mL/min flow rate. The a single-quadrupole mass detector was operated in positive ion mode. Quadrupole mass analyser was employed in selected ion monitoring mode using a target ion at m/z = 46 as [M+H]+. The HILIC-MS method was validated as per International Council on Harmonization (ICH) guidelines in terms of linearity, limit of detection, limit of quantification, selectivity, accuracy, precision and intermediate precision. The main benefit of the HILIC-MS method is a simple sample pretreatment and a quick and sensitive HILIC-MS analysis. The method was demonstrated to be applicable for the determination of DMA in routine quality control evaluation of commercial samples of metformin of both API and dosage forms. The HILIC-MS method was developed as a simpler and faster alternative to compendial method for determination of DMA (as specific impurity F) in MET described in European Pharmacopoeia.

A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.

In this paper, we establish a mechanistic model for the prediction of amorphous solid dispersion (ASD) stability. The novel approach incorporates fundamental physical parameters, principally supersaturation, diffusivity, and interfacial energy, to model crystallization in ASDs accounting for both kinetic and thermodynamic drivers. API dependent decoupling coefficients were also considered which allowed dynamic mechanical analysis to probe molecular mobility, with viscosity measurements, across an exceptionally broad range of temperatures to support ASD stability simulations. ASDs are multicomponent systems in which the amorphous form of active pharmaceutical ingredients (APIs) are molecularly dispersed within a carrier. This gives rise to a transiently supersaturated API solution upon dissolution which increases the driving force for oral absorption and results in increased bioavailability as compared to that of the crystalline API. A major shortcoming of ASDs, however, is that there is the potential for amorphous APIs to revert to their more stable crystalline form during storage, despite the use of polymer carriers to stabilize formulations and limit recrystallization. Hot melt extrusion (HME) has been employed as the preparation method for ASDs used in this study as it is well-suited for the formation of uniform dispersions. The ASDs were stored under controlled temperature conditions, in the absence of humidity, to determine recrystallization kinetics. Our mechanistic model, considering both crystal nucleation and growth processes, describes temporal ASD stability through a system of coupled differential equations that connect the physiochemical properties of the ASD system to drug recrystallization. The model and prolonged time scale of crystallization observed highlight the importance of considering both thermodynamic and kinetic factors in the preparation of stable ASDs. Experimental observations were found to be in good agreement with predictions of the model confirming its utility in predicting the temporal physical stability of amorphous solid dispersions through a mechanistic lens.

Chlorine K-Edge X-ray Absorption Near-Edge Structure Discrimination of Crystalline Solvates and Salts in Organic Molecules

The crystal forms of active pharmaceutical ingredients must be precisely determined to properly regulate their physical properties. In this study, chlorine K-edge X-ray absorption near-edge structu...

Role of solvent in differential phase behavior of celecoxib during spray drying.

Spray drying is an industrially viable technique that can be used for modulation of the physical form of Active Pharmaceutical Ingredients (API), which is governed by inherent crystallization tendency and processing parameters during spray drying. In the current study, we investigated the role of solvent in differential phase behavior of celecoxib, a poor crystallizer, during spray drying and unveiled the underlying mechanisms. 1% w/v solutions of celecoxib in three different compositions of methanol (M)-water (W) solvent system were spray dried using a laboratory spray dryer. The proportions were 0, 5 and 10% v/v of water in methanol (MW0, MW5, and MW10, respectively). Percentage crystallinity of the spray dried products were evaluated using modulated differential scanning calorimetry and was in the order MW10>MW5>MW0 (i.e. 18.52%>8.13%>0%). Solution-state and solid-state crystallization events responsible for the experimental observations were probed using microscopy, Raman spectroscopy, and non-isothermal crystallization studies. An intermediate amorphous phase was generated for the studied samples, which underwent crystallization under the influence of chamber temperature for MW5 and MW10. Additionally, liquid-liquid phase separation (LLPS) at very high level of supersaturation led to relatively higher crystallinity for MW10. Insights from this work provide the basis for understanding of probable phase behavior of poor crystallizers during spray drying.

Development of triflumizole ionic liquids containing anions of natural origin for improving the utilization and minimizing the adverse impacts on aquatic ecosystems

Triflumizole, a broad-spectrum systemic fungicide, has been widely used for the management of fungal diseases in plants. However, rapid photolysis and high risk to the aquatic environment limit its application. Ionic liquid (IL) forms of active pharmaceutical ingredients are innovative and promising agents that can optimize the application of the starting chemicals through the selection, or functionalization of the counterions (cation or anion). In this study, triflumizole was paired with various natural organic acids to develop novel ILs for improving the physicochemical properties and reducing the toxicity to fish. The results showed that the obtained ILs had low surface tension and lipophilicity and could protect triflumizole against degradation under UV irradiation as well as exhibit more excellent biological activity against Botrytis cinerea than triflumizole. The IL forms of triflumizole reduced the dosage and frequency of this fungicide, accordingly minimized the negative effect on environment. The IL contained salicylic acid as anion decreased > 4-fold toxicity to adult zebrafish over TFM. The results reported here create new application possibilities for imidazole fungicides and offer some heuristic rules for the design of active pharmaceutical ingredients-ionic liquids.

Chemometric study of the excipients’ influence on polymorphic-behavior. Mefenamic acid as case of study

The assessment of polymorphism is a problematical issue for regulatory agencies, because variations among crystalline forms of active pharmaceutical ingredient (API) can lead to changes in the efficacy and safety of formulated product. Such conversions are very hard to be detected, thus, the development of techniques for the identification, characterization and quantification of polymorphs results essential in all stages of the manufacturing process.The presence of excipients in formulated products may change the crystal stability of an API, by catalyzing a polymorphic transformation or stabilizing the less stable form. As paradox, all suitable analytical techniques (spectroscopies, thermal analysis, NMR and DRX, and others) for polymorphic analysis are affected by excipients. A deep understanding of the polymorphism-excipient relationship is in full accordance with Quality by Design (QbD) paradigm, the systematic approach focused in quality building into a product based in the full understanding of the products and process.In this work, a novel approach based on thermal stress, MIR monitoring, multivariate curve resolution with alternating least squares (MCR-ALS) and kinetic analysis was developed and applied to monitor polymorphism behavior of model API in formulated products.Commercial tablets, physical mixtures and commercial API, were processed and analyzed under the proposed approach. Commercial tablets of MFA revealed a fast conversion to Form II, contrasting to the behavior of the pure API. Physical mixtures showed similar behavior to commercial tablets, thus reduction in transformation times was related to MFA-excipients physical interaction, even at surface level. Calorimetric studies support the conclusion obtained.The developed approach could be extended to others APIs and other stress sources (humidity, solvents, mechanical forces and its combinations), being a valuable tool for QbD environment.